دورية أكاديمية
Effector T cell chemokine IP-10 predicts cardiac recovery and clinical outcomes post-myocardial infarction.
| العنوان: | Effector T cell chemokine IP-10 predicts cardiac recovery and clinical outcomes post-myocardial infarction. |
|---|---|
| المؤلفون: | Sopova K; Translational and Clinical Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.; Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; Department of Cardiology, Royal Victoria Infirmary (RVI) and Freeman Hospitals, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom.; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Heidelberg/Mannheim, Germany., Tual-Chalot S; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Mueller-Hennessen M; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany., Vlachogiannis NI; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Georgiopoulos G; Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Biener M; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany., Sachse M; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Heidelberg/Mannheim, Germany., Turchinovich A; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Heidelberg/Mannheim, Germany., Polycarpou-Schwarz M; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Heidelberg/Mannheim, Germany., Spray L; Department of Cardiology, Royal Victoria Infirmary (RVI) and Freeman Hospitals, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom.; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Maneta E; Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Bennaceur K; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Mohammad A; Department of Cardiology, Royal Victoria Infirmary (RVI) and Freeman Hospitals, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom.; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Richardson GD; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Gatsiou A; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom., Langer HF; Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany., Frey N; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany., Stamatelopoulos K; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.; Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Heineke J; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Cardiovascular Physiology, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Duerschmied D; Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany., Giannitsis E; Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany., Spyridopoulos I; Translational and Clinical Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.; Department of Cardiology, Royal Victoria Infirmary (RVI) and Freeman Hospitals, Newcastle Upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle Upon Tyne, United Kingdom., Stellos K; Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany.; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Heidelberg/Mannheim, Germany.; Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.; Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany.; Department of Cardiovascular Physiology, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Jun 22; Vol. 14, pp. 1177467. Date of Electronic Publication: 2023 Jun 22 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Myocardial Infarction* , ST Elevation Myocardial Infarction*/therapy, Humans ; Chemokine CXCL10 ; Heart ; Retrospective Studies |
| مستخلص: | Background and Aims: Preclinical data suggest that activation of the adaptive immune system is critical for myocardial repair processes in acute myocardial infarction. The aim of the present study was to determine the clinical value of baseline effector T cell chemokine IP-10 blood levels in the acute phase of ST-segment elevation myocardial infarction (STEMI) for the prediction of the left ventricular function changes and cardiovascular outcomes after STEMI. Methods: Serum IP-10 levels were retrospectively quantified in two independent cohorts of STEMI patients undergoing primary percutaneous coronary intervention. Results: We report a biphasic response of the effector T cell trafficking chemokine IP-10 characterized by an initial increase of its serum levels in the acute phase of STEMI followed by a rapid reduction at 90min post reperfusion. Patients at the highest IP-10 tertile presented also with more CD4 effector memory T cells (CD4 T Conclusion: Increased serum levels of IP-10 in the acute phase of STEMI predict a better recovery in cardiac systolic function and less adverse events in patients after STEMI. Competing Interests: MM-H. reports consulting fees for Zoll CMS GmbH, research funding from Roche Diagnostics and BRAHMS Thermo Scientific. NF has received lecture fees from AstraZeneca, Boehringer Ingelheim, Bayer Vital and consulting fees for Boehringer Ingelheim, all of which not related to the subject in this manuscript. DD reports consulting and speaker fees from Bayer Healthcare, Boston Scientific, Daiichi Sankyo, AstraZeneca, and research grants from DFG, DZHK. EG has received honoraria for lectures from AstraZeneca, Daiichi Sankyo and Roche Diagnostics, consulting fees for BRAHMS Deutschland, Roche Diagnostics, AstraZeneca, Daiichi and Novo Nordisk, research funding from Daiichi and Roche Diagnostics. IS receives research grants from Kancera AB and Astra Zaneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Sopova, Tual-Chalot, Mueller-Hennessen, Vlachogiannis, Georgiopoulos, Biener, Sachse, Turchinovich, Polycarpou-Schwarz, Spray, Maneta, Bennaceur, Mohammad, Richardson, Gatsiou, Langer, Frey, Stamatelopoulos, Heineke, Duerschmied, Giannitsis, Spyridopoulos and Stellos.) |
| References: | J Immunol Res. 2016;2016:4396368. (PMID: 27795961) Nat Med. 2018 Jun;24(6):711-720. (PMID: 29867229) PLoS One. 2012;7(10):e47155. (PMID: 23077561) FASEB J. 2001 Jun;15(8):1428-30. (PMID: 11387246) J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. (PMID: 30153967) Am J Physiol Heart Circ Physiol. 2019 Sep 1;317(3):H581-H596. (PMID: 31322426) Front Cardiovasc Med. 2022 Aug 25;9:992653. (PMID: 36093172) J Clin Invest. 2015 Aug 3;125(8):3063-76. (PMID: 26168217) Annu Rev Immunol. 2004;22:745-63. (PMID: 15032595) JACC Heart Fail. 2020 Feb;8(2):131-140. (PMID: 31838030) Methods Mol Biol. 2011;728:195-206. (PMID: 21468949) Circulation. 1987 Jul;76(1):44-51. (PMID: 3594774) Cardiovasc Drugs Ther. 2018 Aug;32(4):329-338. (PMID: 29956042) J Am Coll Cardiol. 2003 Oct 15;42(8):1446-53. (PMID: 14563590) J Exp Med. 1998 Mar 16;187(6):875-83. (PMID: 9500790) J Mol Cell Cardiol. 2013 Sep;62:24-35. (PMID: 23644221) Circ Res. 2014 Jun 20;115(1):55-67. (PMID: 24786398) Nature. 1999 Oct 14;401(6754):708-12. (PMID: 10537110) Am Heart J. 2011 Oct;162(4):663-70. (PMID: 21982658) Am J Physiol Heart Circ Physiol. 2022 Apr 1;322(4):H622-H635. (PMID: 35179978) Ann Intern Med. 2018 Jun 19;168(12):855-865. (PMID: 29799975) Front Immunol. 2021 May 05;12:605857. (PMID: 34046028) Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30. (PMID: 21802343) Cell Mol Immunol. 2015 Jul;12(4):466-73. (PMID: 25152079) Br J Clin Pharmacol. 2020 Jul;86(7):1387-1397. (PMID: 32067256) Curr Pharm Des. 2014;20(12):1971-9. (PMID: 23844733) Circ Res. 2009 Nov 6;105(10):973-83. (PMID: 19797174) Cardiovasc Res. 2002 Jan;53(1):31-47. (PMID: 11744011) Immun Ageing. 2008 Jul 25;5:6. (PMID: 18657274) Circulation. 2006 Nov 7;114(19):2056-64. (PMID: 17060376) JAMA. 2007 May 2;297(17):1892-900. (PMID: 17473299) J Am Coll Cardiol. 2020 Mar 3;75(8):901-915. (PMID: 32130926) Immunity. 2000 May;12(5):483-94. (PMID: 10843381) J Am Coll Cardiol. 2000 Mar 1;35(3):569-82. (PMID: 10716457) J Exp Med. 1996 Sep 1;184(3):963-9. (PMID: 9064356) Aging Cell. 2020 Oct;19(10):e13249. (PMID: 32996233) Eur Heart J. 2008 Mar;29(6):748-56. (PMID: 18308687) J Clin Invest. 2019 Aug 13;129(11):4922-4936. (PMID: 31408441) Lancet. 2015 Mar 21;385(9973):1114-22. (PMID: 25467573) Cytokine. 2016 Jul;83:147-157. (PMID: 27152707) JCI Insight. 2019 Apr 4;4(7):. (PMID: 30779709) Circulation. 2018 Feb 27;137(9):961-972. (PMID: 29483172) JACC Cardiovasc Imaging. 2022 Sep;15(9):1563-1574. (PMID: 35033494) J Immunol. 2010 Nov 15;185(10):6286-93. (PMID: 20935205) Circulation. 2003 May 27;107(20):2577-82. (PMID: 12732606) Circulation. 2012 Apr 3;125(13):1652-63. (PMID: 22388323) J Cardiovasc Transl Res. 2021 Feb;14(1):35-52. (PMID: 32415537) J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. (PMID: 36368511) Nat Commun. 2021 Mar 5;12(1):1483. (PMID: 33674611) Cytokine. 2016 May;81:63-70. (PMID: 26891076) Mol Immunol. 2018 Sep;101:74-79. (PMID: 29886399) Oxid Med Cell Longev. 2018 Mar 18;2018:1975167. (PMID: 29743973) Am J Epidemiol. 2003 Jun 15;157(12):1101-7. (PMID: 12796046) Cancer Res. 2004 Nov 15;64(22):8451-5. (PMID: 15548717) Immunity. 2005 Feb;22(2):259-70. (PMID: 15723813) |
| معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust |
| فهرسة مساهمة: | Keywords: IP-10; T cells; cardiac MRI; heart failure; lymphocytes; myocardial infarction; prognostic value; remodeling |
| المشرفين على المادة: | 0 (Chemokine CXCL10) |
| تواريخ الأحداث: | Date Created: 20230710 Date Completed: 20230712 Latest Revision: 20231106 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10326041 |
| DOI: | 10.3389/fimmu.2023.1177467 |
| PMID: | 37426649 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1177467 |